JASN: Intravenous iron dose and risk of infection in hemodialysis patients

The results of experimental and observational studies have raised concerns that intravenous injections (IV) of iron in patients (e.gindividuals receiving maintenance hemodialysis) may increase the risk of infectionrecently published a study published in the journal Journal of the American Society of the American Society, hemodialysis patients with forward-looking IV iron treatment (PIVOTAL) trial randomly selected 2,141 ESKD patients receiving maintenance hemodialysis, respectively, with high or low doseIV iron treatment, the main compound outcome of the study was total death, heart attack, stroke or heart failure hospitalizationThe researchers compared infection rates between the two groups in a pre-specified secondary analysisThe secondary endpoint of the study included any infection, hospitalization of infection, and death from infectionThe researchers calculated the cumulative event rates of these endpoints and explored the interaction between iron doses and vascular pathways (fistulas and catheters)found no significant difference in the overall incidence of infection between the high-dose IV iron treatment group and the low-dose group (46.5 percent and 45.5 percent, respectively, with 63.3 and 69.4 per 100 patients per year), respectively; The researchers did find an important link between the risk of the first cardiovascular event and any infection in the previous 30 daysThose who were treated with catheterdialysis had a higher incidence of infection, hospitalization, or infection, but the dose of IV iron had no effect on these results compared to those who were on dialysis through catheterizationit can be seen that the incidence of infection in the high-dose and low-dose groups of IV iron agents is the sameThe risk of the first cardiovascular event is closely related to recent infections